FDA Approves RISEDRONATE SODIUM — Teva Pharmaceuticals USA, Inc.

# FDA Approves Teva Pharmaceuticals' Generic Risedronate Sodium Teva Pharmaceuticals USA, Inc. received FDA approval for its generic formulation of risedronate sodium, a widely-prescribed bisphosphonate used to treat osteoporosis, potentially opening significant market share opportunities as the branded version's exclusivity period ended. The oral generic approval is expected to increase treatment accessibility and drive price competition in the osteoporosis market segment.